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Cell-surface heparan sulfate (HS) serves as an initial attachment receptor for several herpesviruses. The g2-human
herpesvirus-8 (HHV-8) or Kaposi’s sarcoma associated herpesvirus DNA and transcripts have been detected in B cells,
endothelial cells, macrophages, and epithelial cells. HHV-8 infects a variety of human and animal cell lines leading to latent
or abortive infection. Our studies showed that this broad cellular tropism may be in part due to HHV-8’s interaction with the
ubiquitous host cell-surface HS-like molecules. HHV-8 binding to the target cells and the infection were inhibited by soluble
heparan, a glycosaminoglycan (GAG) closely related to HS. Since HHV-8 gB possess a putative heparan-binding domain
(HBD) in the extracellular domain, the interaction of gB with HS-like moieties was examined. Unlike gB of g1-Epstein–Barr
virus and g2-murine herpesvirus 68, HHV-8 gB was expressed on the surface of the infected cell membranes and virion
envelopes. Envelope-associated gB was made up of 75 and 54 kDa polypeptides forming disulfide-linked heterodimers and
multimers. Rabbit anti-gB antibodies neutralized HHV-8 infection. Virion envelope-associated gB specifically bound to
heparan-agarose, which was eluted by high concentration of soluble heparan, but not by chondroitin sulfates. In vitro
transcribed and translated products of gB gene specifically bound to heparan-agarose beads, which was blocked by HS and
heparan, but not by other GAGs such as chondroitin sulfates (A, B, and C), N-acetyl heparan, and de-N-sulfated heparan.
Biotinylated gB peptide corresponding to the putative HBD also bound to heparan. These results suggest that gB plays an
important role in the infectious process of HHV-8 and virus interaction with cell-surface HS-like moieties could be in part
mediated by the envelope-associated gB. © 2001 Academic Press
t
dINTRODUCTION
g2-human herpesvirus-8 (HHV-8) or Kaposi’s sarcoma
associated herpesvirus (KSHV) is a member of the lym-
photropic human g2 herpesvirus family (genus Rhadino-
irus) (Russo et al., 1996; Neipel et al., 1997). HHV-8
sequences have been detected in the KS tissues from
patients with AIDS-KS, Classic KS, African endemic KS,
and transplantation-associated KS (Chang et al., 1994;
Schulz et al., 1998). HHV-8 DNA and transcripts have
been also identified in human B cells (Whitby et al., 1995),
macrophages (Blasig et al., 1997), keratinocytes (Boshoff
et al., 1995; Staskus et al., 1997), endothelial cells (Schulz
et al., 1998), and epithelial cells (Diamond et al., 1998).
HHV-8 has been shown to infect a variety of cell types in
vitro, including human B, endothelial, epithelial, and fi-
broblast cells, as well as owl monkey kidney and baby
hamster kidney fibroblast cells (Blackbourn et al., 2000;
enne et al., 1996; Vieira et al., 2001). However, a sus-
tained, productive HHV-8 infection has not yet been es-
tablished and inoculation of these cell types usually
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Microbiology, Molecular Genetics and Im-
unology, University of Kansas Medical Center, 3901 Rainbow Blvd.,ansas City, KS 66160-7424. Fax: (913)588-7295. E-mail: bchandra@
umc.edu
235results in an abortive and/or latent infection (Blackbourn
et al., 2000; Renne et al., 1996; Vieira et al., 2001).
In a recent study, we showed that the broad cellular
tropism of HHV-8 may be due to its ability to bind the
ubiquitous cell-surface HS-like moieties (Akula et al.,
2001). HHV-8 infection of human foreskin fibroblast (HFF)
cells was inhibited in a dose-dependent manner by sol-
uble heparan, a glycosaminoglycan (GAG) closely re-
lated to HS. Enzymatic removal of HS from HFF cell
surfaces with heparanase I and III reduced HHV-8 infec-
tion. Soluble heparan inhibited the binding of radiola-
beled HHV-8 to human B cell lines, embryonic kidney
epithelial (293) cells, and HFF cells, suggesting interfer-
ence at the virus attachment stage. Cell-surface ad-
sorbed HHV-8 was displaced by soluble heparan. Radio-
labeled HHV-8 also bound to wild-type HS expressing
Chinese hamster ovary (CHO-K1) cells. In contrast, bind-
ing of virus to mutant CHO cells deficient in HS was
significantly reduced (Akula et al., 2001).
Our studies suggested that the g2-HHV-8 resembles
some members of a-herpesviruses [herpes simplex virus
ype1 (HSV-1); herpes simplex virus type 2 (HSV-2); pseu-
orabies virus (PRV); bovine herpesvirus type 1 (BHV-1)],
b-herpesviruses [human cytomegalovirus (HCMV); hu-
man herpesvirus 7 (HHV-7)], and g2-herpesvirus [bovine
herpesvirus-4 (BHV-4)], where the initial virus-cell inter-
action also involves the binding to the cell-surface HS-
0042-6822/01 $35.00
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236 AKULA ET AL.like moieties (Liang et al., 1993; Mettenleiter et al., 1990;
Neyts et al., 1992; Secchiero et al., 1997; Skrincosky et al.,
2000; Vanderplasschen et al., 1993; WuDunn and Spear,
1989). In a-herpesviruses, glycoproteins gB and gC are
nown to bind HS during the initial step of viral entry into
he cells (Mettenleiter et al., 1990; Herold et al., 1994).
The gC homolog of a-herpesviruses is absent in b- and
g-herpesviruses. Instead, the gB in the b-herpesviruses
HCMV, HHV-7) and g2-herpesvirus (BHV-4) have been
hown to mediate the HS binding of these viruses (Neyts
t al., 1992; Secchiero et al., 1997; Vanderplasschen et
l., 1993).
The identity of HHV-8 envelope glycoprotein(s) in-
olved in the interaction with HS-like moieties is not
nown. HHV-8 encodes for more than 80 ORFs. The
RFs 1 to 75 designation is based on the similarity to
erpesvirus saimiri (HVS) ORFs. HHV-8 unique ORFs are
esignated with the prefix K (Russo et al., 1996; Neipel et
l., 1997). HHV-8 has counterparts to other herpesvirus
lycoproteins such as glycoproteins gB (ORF 8), gH (ORF
2), gM (ORF 39), and gL (ORF47). In addition to these
onserved glycoproteins, K1 and K8.1 genes encode for
lycoproteins unique for HHV-8 (Russo et al., 1996;
eipel et al., 1997; Chandran et al., 1998).
By analyzing heparan-binding proteins, Cardin and
Weintraub (1989) have proposed two consensus motifs
for the heparan-binding domain (HBD) of polypeptides.
Each is composed of a core of basic amino acids flanked
by an additional positively charged residue separated by
hydrophobic amino acids, e.g., XBBXBX or XBBBXXBX,
where B is a basic amino acid and X is a hydrophobic
residue. Heparin-binding proteins often contain more
than one of these sequences. Predictive analysis of
HHV-8 sequence revealed the presence of putative HBD
in HHV-8 gB and gpK8.1A. HHV-8 gB is composed of 845
amino acids (aa) and possesses the BXXBXBBXBB
(HIFKVRRYRK) -type HBD within the extracellular domain.
Since the virion envelope gBs of other herpesviruses
have been shown to interact with the host cell-surface
HS (Cai et al., 1988; Highlander et al., 1988; Navarro et al.,
993; Spear, 1993), here we have examined HHV-8 gB
nteractions with HS-like moieties.
There are two contradictory reports about HHV-8 gB
xpression in cells (Pertel et al., 1998; Baghian et al.,
000). Pertel et al. (1998) used HHV-8 gB with a hemag-
lutinin (HA) tag to study the expression of the protein in
HO-K1 cells and identified an endoglycosidase H-sen-
itive glycosylated HHV-8 gB-HA protein of about 120
Da. HHV-8 gB-HA expression was restricted around the
erinuclear area of CHO-K1 cells with no apparent move-
ent to the periphery (Pertel et al., 1998). Even though gB
xpressions in HHV-8-infected BCBL cells and virion
ere not examined, Pertel et al. (1998) concluded that
HV-8 gB was not processed in the Golgi and thusesembles g1-Epstein–Barr virus (EBV)-gB, which is re-
tained in the endoplasmic reticulum and nuclear mem-
w
Gbrane but not expressed on the infected cell membranes
and virion envelopes (Gong and Kieff, 1990). Baghian et
al. (2000) have raised rabbit antibodies against gB pep-
tides corresponding to the amino (aa 27–42, aa 167–191)
and carboxyl (aa 828–845) domains of HHV-8 gB. Studies
with these antibodies suggested that gB in the BCBL-1
cells is synthesized as a 110-kDa precursor molecule
and undergoes cleavage resulting in two smaller protein
species of about 75 and 59 kDa, corresponding to the
amino- and carboxyl-terminal portions of gB. In addition,
these antibodies also detected a full-length 112 kDa gB
as well as 75 and 59 kDa proteins from HHV-8 virions
purified from BCBL-1 cells (Baghian et al., 2000). At
amino acid position 440–441 in the HHV-8 gB sequence,
there is a potential proteolytic cleavage site (RKRR/S)
and cleavage at this site would result in two proteins
with the predicted molecular weights of about 48 and 45
kDa. Endo-F and Endo-H enzyme treatments detected
the presence of complex and high mannose sugars in
HHV-8 gB. HHV-8 was detected throughout the cyto-
plasm of HHV-8-harboring BCBL-1 cells and in trans-
fected Vero cells. In contrast, HHV-8 gB was expressed
only as a full-length 107-kDa protein in COS-1 cells
without cleavage (Baghian et al., 2000). We have also
observed similar results in COS-1 cells transfected with
plasmid encoding gB and Endo-F and Endo-H enzyme
treatments detected the presence of complex and high
mannose sugars in HHV-8 gB expressed in COS-1 cells
(unpublished observation). This suggested that gB cleav-
age resulting in the amino- and carboxyl-terminal por-
tions may be due to a protease in BCBL-1 cells. The
differences in HHV-8 gB distribution detected in the CHO,
COS-1, and BCBL-1 cells can be attributed to the different
processing in the different cell lines, relative amounts of
gB expressed, and the use of different antibodies.
The study of Baghian et al. (2000) did not examine the
HHV-8 gB expression on the surface of the infected cell
membranes and the nature of gB in the virion envelopes.
Because of these contradictory reports about HHV-8 gB
expression in cells, we initially examined the localization
of gB in the infected cells and in the virus before pro-
ceeding with the study of HS and heparan interaction.
Our studies demonstrate that unlike gB of g1-EBV and
g2-murine herpesvirus 68 (MHV-68) (Gong and Kieff,
1990; Stewart et al., 1994), HHV-8 gB is expressed on the
urface of the infected cell membranes and on the virion
nvelopes. Envelope-associated gB is made up of 75
nd 54 kDa polypeptides forming disulfide-linked het-
rodimers and multimers. Rabbit anti-gB antibodies neu-
ralized HHV-8 infectivity. Virion envelope-associated gB
as precipitated by heparan-agarose, which was eluted
ith a high concentration of soluble heparan. In vitro
ranscribed and translated products (IVT) from the gB
ene specifically bound to heparan-agarose beads,
hich was blocked by heparan and HS, but not by other
AGs. Biotinylated gB peptide corresponding to the pu-
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237HHV-8 gB BINDS HEPARAN SULFATE-LIKE MOIETIEStative HBD also bound to heparan. Taken together, these
results demonstrate a role for gB in the infectious pro-
cess of HHV-8 and in the interaction with HS-like moi-
eties.
RESULTS
Specificity of the rabbit Anti-HHV-8 gB antibody
HHV-8 gB from BCBL-1 cells was cloned into the
eukaryotic expression plasmid pCDNA3.1(1) and veri-
fied by sequencing. HHV-8 gB ORF consists of 845 aa
and is predicted to encode a protein of about 94 kDa
(Russo et al., 1996; Neipel et al., 1997). IVT of gB-
pCDNA3.1(1) plasmid resulted in the generation of a
[35S]methionine-labeled specific protein of about 96 kDa
Fig. 1, lane 2), which shifted into a glycosylated protein
f about 126 kDa in the presence of microsomal mem-
ranes (Fig. 1, lane 3). These results confirmed the au-
henticity of full-length gB ORF. HHV-8 gB was expressed
s a GST-gB fusion protein, purified, and used to immu-
ize the rabbits. Nonspecific antibodies from the rabbit
nti-gB IgG antibodies were removed by passing over
epharose columns coupled with purified GST protein
nd BJAB cell lysate proteins. Rabbit anti-gB IgG anti-
odies specifically immunoprecipitated both the nongly-
osylated (Fig. 1, lane 6) and glyosylated forms of gB (Fig.
FIG. 1. In vitro transcription and translation of HHV-8 gB gene and the
pecificity of rabbit anti-gB antibodies. The gB-pCDNA3.1(1) plasmids
nd control pCDNA3.1(1) plasmids were in vitro transcribed and trans-
ated in the TNT system using rabbit reticulocyte lysates and [35S]me-
hionine. Lane 1: IVT products from the pCDNA3.1(1) plasmid. Lanes 2
nd 3: IVT products from the gB-pCDNA3.1(1) plasmid in the absence
r presence of microsomal membranes, respectively. Equal TCA pre-
ipitable radioactive counts were analyzed. Lanes 4 and 5: immuno-
recipitation of IVT products from the gB-pCDNA3.1(1) plasmid in the
bsence or presence of microsomal membranes, respectively, by the
abbit anti-gpK8.1A IgG antibodies. Lanes 6 and 7: immunoprecipitation
f IVT products from the gB-pCDNA3.1(1) plasmid in the absence or
resence of microsomal membranes by the rabbit anti-gB IgG antibod-
es. Samples were run on 10% SDS–PAGE gels and autoradiographed.
he numbers on the left indicate the approximate molecular mass (in
ilodaltons) of standard proteins run in parallel lanes. The major IVT
onglycosylated (NG) and glycosylated (G) forms of HHV-8 gB protein
re indicated on the right., lane 7). Rabbit anti-gB IgG antibodies did not show any
eactivity with IVT products from HHV-8 gL, gH, and
t
gpK8.1A containing plasmids (data not shown). Rabbit
nti-HHV-8 gpK8.1A antibodies (Zhu et al., 1999a) did not
mmunoprecipitate the nonglycosylated or glycosylated
orms of gB (Fig. 1, lanes 4 and 5). These results dem-
nstrated the specificity of rabbit anti-HHV-8 gB antibod-
es and the immunoprecipitation reactions. This anti-gB
gG antibody was used throughout the study.
HV-8 gB is expressed on the surface of the infected
ells and virion envelopes
Glycoprotein gB is highly conserved among the mem-
ers of herpesvirus family and expressed on the surface
f the infected cells and virion envelopes of several a-
HSV-1, HSV-2, PRV, BHV-1), b- (HCMV, HHV-6, HHV-7)
nd g- (BHV-4) herpesviruses (Liang et al., 1993; Metten-
leiter et al., 1990; Neyts et al., 1992; Secchiero et al., 1997;
Vanderplasschen et al., 1993; WuDunn and Spear, 1989).
However, the gB of g1-EBV and g2-MHV-68 were not
etected on the cell surfaces and virion envelopes (Gong
nd Kieff, 1990; Stewart et al., 1994). To determine
hether g2-HHV-8 gB plays a functional role in the virus
nteraction with host cell-surface HS and infectivity, the
istribution of gB in HHV-8-infected cells and in the virion
nvelopes were first examined by IFA and IEM.
About 1–3% of HHV-8 carrying BCBL-1 cells spontane-
usly enter lytic cycles and about 15–20% of TPA-induced
ells express viral lytic cycle proteins (Chandran et al.,
998; Zhu et al., 1999a). Rabbit anti-gB antibodies did not
eact with acetone-fixed TPA-induced HHV-8-negative
JAB cells (data not shown). In contrast, with about
5–20% of TPA induced BCBL-1 cells, rabbit anti-gB an-
ibodies showed a very bright cytoplasmic fluorescence
redominantly localized in the cytoplasm and plasma
embranes (Fig. 2A). Reactivities with only a limited
ercentage of TPA-induced cells representing cells ex-
ressing lytic cycle proteins also demonstrated the spec-
ficity of rabbit anti-gB antibodies.
To determine whether the gB protein was expressed
n the infected cell plasma membranes, TPA-induced
CBL-1 cells were fixed with 0.1% paraformaldehyde and
ested with the rabbit anti-gB antibodies in surface IFA.
o reactivity was seen with uninduced and TPA-induced
JAB cells (data not shown). About 10–15% of the TPA-
nduced BCBL-1 cells showed surface immunofluores-
ence with the anti-gB antibodies demonstrating the
xpression of HHV-8 gB on the infected cell plasma
embranes (Fig. 2B).
The cell-surface localization of gB in the HHV-8-in-
ected BCBL-1 cells was further confirmed by IEM. Rabbit
nti-gB IgG antibodies did not show any reactivity with
PA-induced BJAB cells (data not shown). In contrast,
old particles were detected on the surfaces of about
0% of TPA-induced BCBL-1 cells 24 h after TPA induc-
ion (Fig. 3A). These results confirmed the presence of
B on the infected BCBL-1 cell membranes. Examination
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238 AKULA ET AL.of the cell surfaces by IEM at 24 h post-TPA induction
revealed only a few virus particles (data not shown),
while virus particles were readily detected at 92 h post-
TPA induction. However, the morphology of cells at 92 h
was considerably deteriorated. Despite this, gold parti-
cles were detected on the surfaces of virion particles in
FIG. 2. Immunofluorescence reactivities of rabbit anti-gB antibodies w
and collected after 4 days. (A) Reactivities of rabbit anti-gB IgG antibo
anti-gB IgG antibodies in SIFA with 0.1% paraformaldehyde-fixed TPA-i
FIG. 3. Reactivities of rabbit anti-gB antibodies in immune electron m
fixed with 0.1% paraformaldehyde. Dilutions of rabbit anti-gB IgG antibo
ncubated at 37°C for 30 min with goat anti-rabbit IgG antibodies conju
% glutaraldehyde, and embedded in resins. Thin sections were made
CBL-1 cells after 24 h post-TPA induction. Magnification: 56,0003. Arr
) Reactivities of rabbit anti-gB IgG antibodies with BCBL-1 cells after 96 h
nvelopes. Magnification: B, 87,0003; C and D, 82,0003.samples incubated with rabbit anti-gB antibodies (Figs.
3B–3D). No reactivity was seen with Mab 11D1 recog-
nizing the HHV-8 non-envelope-associated ORF 59 (PF-8)
protein (Zhu et al., 1999a). These results demonstrated
that HHV-8 gB is a virion envelope-associated glycopro-
tein.
V-8 carrying BCBL-1 cells. Cells were stimulated with 20 ng/ml of TPA
ith acetone-fixed TPA-induced BCBL-1 cells. (B) Reactivities of rabbit
BCBL-1 cells.
py. BCBL-1 cells were stimulated with 20 ng/ml of TPA, collected, and
re incubated with 106 cells at 37°C for 30 min, washed five times, and
ith 15-nm gold particles. The cells were washed five times, fixed with
d, and examined. (A) Reactivities of rabbit anti-gB IgG antibodies with
s indicate the gold particles on the surface of BCBL-1 cells. (B, C, andith HHicrosco
dies we
gated w
, staine
owheadpost-TPA induction. Arrows indicate the gold particles on the virion
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239HHV-8 gB BINDS HEPARAN SULFATE-LIKE MOIETIESTo determine the molecular identity of virion envelope-
associated HHV-8 gB, purified HHV-8 was labeled
with125I, solubilized, and centrifuged at 100,000 g. The
esulting supernatant containing the soluble-labeled en-
elope proteins was used in immunoprecipitation reac-
ions. When this 125I-labeled total soluble virion envelope
protein preparation was resolved by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS—
PAGE), proteins of about 115, 75, 72–68, 54, 42, 33, and 24
kDa were detected (Fig. 4A); among these, 75 and 72–68
kDa bands were prominent. Detection of limited proteins
demonstrated the relative purity of the virus preparation.
Rabbit anti-gB antibodies specifically immunoprecipi-
tated two polypeptides of about 75 and 54 kDa from the
125I-labeled virion lysates (Fig. 4B, lane 2). When nonre-
uced samples were analyzed, the 75 and 54 kDa
olypeptides were replaced by the broadly migrating
olypeptides of about 120–135 kDa (Fig. 4B, lane 4).
aintly labeled polypeptides of about 190 and 215 kDa
ere also detected (Fig. 4B, lane 4). Rabbit preimmune
gG antibodies did not immunoprecipitate any of the gB
pecific bands (Fig. 4B, lanes 1 and 3).
At amino acid position 440–441 in the HHV-8 gB se-
uence, there is a potential proteolytic cleavage site
RKRR/S) and cleavage at this site would result in two
FIG. 4. Reactivities of rabbit anti-gB antibodies with 125I-labeled HH
oncentrated, purified, and labeled with125I. Labeled virus was concentra
g. The resulting 125I-labeled supernatant containing soluble envelope p
ndicate the approximate molecular mass (in kilodaltons) of standard pr
by 12% SDS–PAGE. The asterisks denote the proteins with an approxim
oluble envelope proteins immunoprecipitated with rabbit preimmune
mmunoprecipitated samples were boiled in sample buffer with 2-ME (
ample). Equal radioactive counts were analyzed by a 7.5% SDS–PAGE
olecular mass (in kilodaltons) of major envelope-associated HHV-8 groteins with the predicted molecular weights of about
8 and 45 kDa. Baghian et al. (2000) studies showed thathe BCBL-1 cells associated with gB is synthesized as a
10-kDa precursor molecule and undergoes cleavage,
esulting in two species of about 75 and 59 kDa corre-
ponding to the amino- and carboxyl-terminal portions of
B. The 75 and 54 kDa proteins immunoprecipitated from
he virion envelope probably represent the glycosylated
ature forms of the cleaved amino- and carboxyl-termi-
al portions of HHV-8 gB, respectively. These results
howed that HHV-8 gB is incorporated in the viral enve-
ope as cleaved products forming dimers and multimers.
n addition, the absence of other protein(s) under the
onditions of our reactions showed that HHV-8 gB was
ot complexed with other viral proteins in the virion
nvelope.
abbit Anti-gB antibodies neutralize HHV-8 infection
Since the expression of HHV-8 gB on the viral enve-
ope suggests a potential involvement in the interaction
ith host cells, the ability of rabbit anti-gB antibodies to
eutralize HHV-8’s infectivity was examined. Although
HV-8 has a broad in vivo cellular tropism, analysis of in
vitro HHV-8 interaction with host cells and quantitation of
infection has been hampered by the absence of a lytic
replication cycle and a reliable plaque assay. In addition,
V-8 virions from the supernatant of TPA-induced BCBL-1 cells were
100,000 g, lysed with RIPA buffer, sonicated, and centrifuged at 100,000
was used in immunoprecipitation reactions. The numbers on the left
un in parallel lanes. (A) 125I-labeled soluble envelope proteins analyzed
lecular mass of 115, 75, 72–68, 54, 42, 33, and 24 kDa. (B) 125I-labeled
ntibodies (lanes 1 and 3) or anti-gB IgG antibodies (lanes 2 and 4).
and 2, reduced sample) or without 2-ME (lanes 3 and 4, nonreduced
autoradiographed. The numbers on the right indicate the approximate
eins.V-8. HH
ted at
roteins
oteins r
ate mo
IgG a
lanes 1infection is often abortive and only a low percentage of
HHV-8-infected human endothelial or HFF cells retained
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240 AKULA ET AL.the viral genome in a latent form as evidenced by the
presence of circular HHV-8 representing latent DNA and
by the expression of HHV-8 latency-associated nuclear
antigen (LANA-1) encoded by the ORF 73 gene (Black-
bourn et al., 2000; Renne et al., 1996; Vieira et al., 2001).
The earliest time point of LANA-1 detection by IFA was
after 72 h. To monitor the HHV-8 binding and entry
process, we used a recombinant HHV-8 (GFP-HHV-8)
expressing the green fluorescent protein (Vieira et al.,
2001). Infection of HFF cells with 100 ml of GFP-HHV-8
tock virus resulted in approximately 150 green fluores-
ent protein expressing cells per well. The expression of
FP as an indicator of HHV-8 entry and infection was
lso confirmed by the detection of LANA-1 in GFP ex-
ressing cells (Akula et al., 2001; Vieira et al., 2001).
pecificity of GFP-HHV-8 entry and infection was also
erified by neutralization assays using sera from HIV 1
S1 individuals (manuscript in preparation). Even
hough the expression of GFP under the control of pro-
iscuous elongation factor-1-a promoter was evident 1
day postinfection, the green fluorescence signals were
weaker and difficult to quantitate. However, the intensity
of fluorescence signals increased and were clearly evi-
dent after 3 days postinfection. Since only a latent infec-
tion was observed in the HFF cells without the expres-
sion of lytic cycle proteins and infectious viruses, the
GFP expressing cells represent infection by the input
virus and are not due to reinfection by the spread of
replicating viruses from the infected cells.
Rabbit anti-gB antibodies neutralized HHV-8 infection
of HFF cells in a dose-dependent manner (Fig. 5). A 50%
inhibition of HHV-8 infectivity was seen with 30 mg/ml of
nti-gB IgG antibodies, which increased to over 70%
nhibition at a concentration of 60 mg/ml of anti-gB IgG
Fig. 5). HHV-8 infectivity was not inhibited by rabbit
reimmune IgG antibodies (Fig. 5) or by rabbit anti-
RF73 IgG antibodies (data not shown), thus demon-
trating the specificity of HHV-8 neutralization by anti-gB
ntibodies. These results suggested that the virion en-
elope-associated gB plays an important role in the in-
ectious process of HHV-8.
irion envelope-associated gB binds heparan-agarose
Heparin is closely related to HS and inhibition of virus
nfectivity by heparan treatment has been considered as
vidence for members of a-, b-, and g2-herpesviruses
interaction with cell-surface HS molecules (Liang et al.,
1993; Mettenleiter et al., 1990; Neyts et al., 1992; Secchi-
ero et al., 1997; Skrincosky et al., 2000; Spear, 1993;
Vanderplasschen et al., 1993; WuDunn and Spear, 1989).
n a recent study, we showed that the HHV-8 interaction
ith host cell surfaces involved HS and that heparan
locked HHV-8 binding and infection (Akula et al., 2001).
equence analyses showed that HHV-8 gB possesses
he BXXBXBBXBB (HIFKVRRYRK) -type HBD within the
o
(xtracellular domain. Comparison of the putative HBD
omain of HHV-8 gB with gB of a-, b-, and g-herpesvi-
ruses showed that this potential HBD is highly con-
served among the gB of g2-herpes viruses (Table 1).
mong the g2-herpes viruses, only g2 BHV-4 gB has
een so far shown to interact with HS and heparan
Vanderplasschen et al., 1993).
The potential role of HHV-8 gB interactions with host-
cell HS-like moieties was studied by analyzing the ability
of envelope-associated gB to bind heparan. Biotinylated
purified virus was lysed with RIPA buffer, sonicated, and
centrifuged at 100,000 g. The resulting supernatant con-
taining the soluble biotinylated envelope proteins was
mixed with heparan-agarose or agarose beads for 2 h at
4°C and washed. The bound material was eluted by
boiling in sample buffer, resolved by SDS–PAGE, West-
ern blotted, and analyzed with AP-labeled streptavidin
(Fig. 6). Polypeptides of about 30–45 kDa precipitated
both by agarose and by heparan-agarose were consid-
ered as nonspecific bands (Fig. 6, lanes 1 and 2).
Polypeptides of about 75, 72, and 54 kDa were specifi-
cally precipitated by heparan-agarose beads only (Fig. 6,
lane 2). Preincubation of soluble biotinylated proteins
with 350 mg of heparan or HS prevented the interaction
FIG. 5. Dose-dependent inhibition of HHV-8 infection by rabbit
anti-gB IgG antibodies. A fixed quantity (100 ml) of GFP-HHV-8 was
ncubated at 37°C for 1 h with DMEM alone or with DMEM containing
ifferent concentrations (0, 7.5, 15, 30, and 60 mg/ml) of rabbit anti-gB or
preimmune IgG antibodies. HFF cell monolayers in eight-well chamber
slides were infected with these mixtures at 37°C for 2 h, washed twice
with DMEM, and further incubated with growth medium at 37°C for 3
days. Green fluorescent cells indicative of GFP-HHV-8 entry and infec-
tion were counted using a digital imaging system. In control wells after
infection with 100 ml of HHV8-GFP stock virus, approximately 150 green
luorescent expressing HFF cells per well were detected. Each reaction
as done in triplicate and each point represents the average 6 SD of
three experiments.f these specific proteins with heparan-agarose beads
data not shown). When the heparan-agarose beads-
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241HHV-8 gB BINDS HEPARAN SULFATE-LIKE MOIETIESbound proteins were eluted and reacted with rabbit pre-
immune IgG antibodies, no reaction was seen in the
Western blot reactions (Fig. 6, lane 3). In contrast, the
anti-gB antibodies specifically recognized the 75 and 54
kDa bands from the proteins bound to heparan-agarose
beads (Fig. 6, lane 4). Anti-gB antibodies did not react
with the proteins bound to agarose beads (data not
shown). The identity of the 72-kDa heparan-agarose in-
teracting HHV-8 envelope glycoprotein is under investi-
gation. These results demonstrated the ability of virion
envelope-associated gB to interact with HS-like moieties.
The characteristics of these interactions was further ex-
amined.
Displacement of heparan-agarose adsorbed virion
envelope-associated gB by heparan
Soluble heparan reversed the attachment of HHV-8 to
the target cells (Akula et al., 2001). To ascertain the
pecificity of virion envelope-associated gB interaction
ith heparan-agarose beads, 125I-labeled virion envelope
lysate was first allowed to bind heparan-agarose beads
T
Comparison of the Putative Heparin Binding Dom
Herpesviruses Herpesvirus gB sequences
a-herpesviruses
HSV-1 Y K F
HSV-2 Y K F
PRV H K F
BHV-1 Y T F
b-herpesviruses
HCMV H T F
HHV-7 H T F
g1-herpesviruses
EBV Y S F
g2-herpesviruses
HVS Y I F
MHV-68 Y I F
BHV-4 Y I F
AtHV-3 H I F
AHV-1 Y V F
EHV-2 Y V F
EHV-5 Y I F
RRV26-95 H I F
RRV17577 H I F
HHV-8 H I F
onsensus sequence H I F
BD motif B X X
Two consensus motifs for the heparan-binding domain (HBD) were pr
s composed of a core of basic amino acids (B) flanked by an additi
eparin-binding proteins often contain more than one of these sequen
xtracellular domain (108–117 aa). This sequence was compared us
esource (Barker et al., 2000). This region is highly conserved among
old and the conservative substitution of amino acids are italicized.
acaca mulatta rhadinovirus 26-65; RRV17577, Macaca mulatta rhadinand the bound fraction was displaced with a high con-
centration (2 mg/ml) of soluble chondroitin sulfates or
w
nheparan. The proteins displaced from the heparan-aga-
rose beads were then immunoprecipitated with rabbit
anti-gB and preimmune control IgG antibodies. The sen-
sitivity of these reactions with 125I-labeled virion lysate
as comparatively higher than with the biotinylated
irion lysates (data not shown). Immunoprecipitation of
he heparan-agarose unbound fraction with rabbit
nti-gB and control IgG antibodies did not reveal any
etectable protein (Fig. 7, lanes 3 and 4). Chondroitin
ulfate C even at a concentration of 2mg/ml could not
isplace the gB bound to heparan-agarose beads as
videnced by the absence of gB in the immunoprecipi-
ation reactions with the chondroitin sulfate C eluate (Fig.
, lanes 5 and 6). Similar results were also seen with
hondroitin sulfates A and B (data not shown). In con-
rast, 2 mg/ml of heparan displaced gB bound to hepa-
an-agarose beads as evidenced by the immunoprecipi-
ation of 75 and 54 kDa proteins from the heparan eluate
y the anti-gB antibodies (Fig. 7, lane 7). Rabbit preim-
une antibodies did not precipitate any detectable pro-
ein from the heparan eluate (Fig. 7, lane 8). HHV-8 gB
HHV-8 gB with gB of a-, b- and g-Herpesviruses
ilarity to the putative heparan binding domain of HHV-8 gB
A T M Y Y K
A T M Y Y K
A H I Y Y K
A Y I Y K N
V R V Y Q K
V R T F K K
V R S Y T K
V R R Y K K
I R R Y R K
V R K Y R K
V R R Y K K
V R R Y R K
V R K Y R K
V R R Y R K
V R R Y R K
V R R Y R K
V R R Y R K
V R R Y R K
X B B X B B
by Cardin and Weintraub (1989) for the heparan binding proteins. Each
sitively charged residue separated by hydrophobic amino acids (X).
HV-8 gB possesses BXXBXBBXBB (HIFKVRRYRK)-type HBD within the
tif comparisons software and database from the Protein Information
mbers of g2-herpesvirus family. Conserved amino acids are shown in
, ateline herpesvirus 3; AHV-1, alcelaphine herpesvirus 1; RRV26-95,
17577.ABLE 1
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242 AKULA ET AL.heparan moieties in the heparan-agarose beads and not
to the agarose. Taken together, these results confirmed
the specificity of virion envelope-associated HHV-8 gB
binding to heparan.
HHV-8 gB specifically binds to HS and heparan
To verify the HHV-8 gB interaction with HS-like moi-
eties, the ability of uncleaved IVT gB to bind heparan-
agarose beads was tested. The IVT reactions in the
presence of microsomal membranes yielded both the
underglycosylated and the glycosylated forms of gB,
which specifically bound to heparan-agarose beads (Fig.
8A, lane 1), but not to the agarose beads (Fig. 8A, lane 2).
The IVT products from HHV-8 gL-pCDNA3.1(1) and
pCDNA3.1(1) plasmids did not bind to either heparan-
agarose or agarose beads (data not shown), demonstrat-
ing the specificity of IVTgB-heparan interaction. Specific-
ity of this reaction was also assessed by the ability of
various GAGs to compete with the heparan-binding ac-
tivity of IVT gB. Interaction of gB with the heparan-aga-
rose beads was competitively inhibited by the addition of
FIG. 6. Virion envelope-associated gB binding with heparan-agarose.
Biotin-labeled purified HHV-8 was lysed with RIPA buffer, sonicated,
and centrifuged at 100,000 g at 4°C for 1 h. The resulting supernatant
containing soluble biotinylated envelope proteins was mixed with
heparan-agarose or agarose beads at 4°C for 2 h and washed five
times in RIPA buffer. The bound material was eluted by boiling the
beads in sample buffer with 2-ME, resolved by 10% SDS–PAGE, West-
ern blotted, and analyzed. Lane 1: biotinylated proteins eluted from the
agarose beads reacted with AP-labeled streptavidin and substrate.
Lane 2: biotinylated proteins eluted from the heparan-agarose beads
reacted with AP-labeled streptavidin and substrate. Lane 3: proteins
eluted from the heparan-agarose beads in Western blot reactions with
rabbit preimmune IgG antibodies. Lane 4: proteins eluted from the
heparan-agarose beads in Western blot reactions with rabbit anti-gB
IgG antibodies. The numbers on the left indicate the molecular masses
(in kilodaltons) of the standard protein markers run in parallel lanes.350 mg/ml of heparan (Fig. 8A, lane 3) and 350 mg/ml of
HS (Fig. 8A, lane 4) to the reaction mixture. In contrast,
g
i350 mg/ml of chondroitin sulfate A, B, and C, N-acetyl
heparan, and de-N-sulfated heparan did not inhibit the
gB interaction with the heparan-agarose beads (Fig. 8A,
lanes 5, 6, 7, 8, and 9). These results confirmed the
specificity of IVT-gB interactions with heparan and HS.
HHV-8 gB binding to heparan-agarose beads was also
examined by pretreating glycosylated IVT gB with differ-
ent concentrations of heparan at 4°C for 1 h and incu-
bating with heparan-agarose beads at 4°C for 2 h. The
autoradiographs were analyzed by densitometer scan-
ning and the percentage inhibition was calculated. Hep-
arin at 350 mg/ml inhibited the gB binding to heparan-
agarose beads to almost undetectable levels (.95% in-
hibition) (Fig. 8B, lane 2). Heparin at 175, 88, 44, 22, and
11 mg/ml concentrations inhibited the binding of gB to
eparan-agarose beads by about 93, 82, 66, 58, and 53%,
espectively (Fig. 8B, lanes 3–7). This dose-dependent
nhibition by heparan further confirmed the specificity of
B interaction with heparan-agarose beads.
The nonglycosylated form of gB [gB (NG)] from the IVT
eaction of gB-pCDNA3.1(1) plasmid without microsomal
embranes also bound the heparan-agarose beads (Fig.
C, lane 4). Heparin-agarose did not precipitate any
roteins from the IVT products from control pCDNA3.1(1)
lasmid (Fig. 8C, lane 1) and HHV-8 gL-pCDNA3.1(1)
lasmid (Fig. 8C, lane 3). Interaction of HHV-8 gB (NG)
ith the heparan-agarose beads was competitively in-
ibited by the addition of 350 mg/ml heparan (Fig. 8C,
lane 5) and 350 mg/ml HS (Fig. 8C, lane 6) to the reaction
mixture. In contrast, 350 mg/ml chondroitin sulfate A, B,
nd C did not inhibit the gB (NG) interaction with the
eparan; the results with chondroitin sulfate C is shown
n Fig. 8C, lane 7. These results demonstrated that the
lycosylation modification was not essential for the gB
nteraction with heparan and HS.
dentifying a potential HBD in gB
To determine whether HHV-8 gB’s BXXBXBBXBB-type
BD (HIFKVRRYRK, 108–117 aa; gB-H1) is involved in the
HV-8 gB interaction with HS-like moieties, biotinylated
eptides were tested for their heparan-binding proper-
ies using BSA-heparan and BSA in an ELISA. In addition
o gB-H1 peptide, the gB-H2 peptide (DAISVTECIN, 521–
30 aa) with acidic residues was used as control. Since
he virion envelope-associated gpK8.1A also possesses
BD, gpK8.1A-H1 (TRGRDAHY, 182–189 aa) and
pK8.1A-H2 (SRTTRIRV, 150–157 aa) were also used. The
B-H1 peptide with a BXXBXBBXBB-HBD and the
pK8.1A-H1 peptide with a XBXBXXBX-HBD bound to
SA-heparan (Fig. 9). In contrast, the gpK8.1A-H2 peptide
ith the XBXXBXBX-HBD and the gB-H2 peptide with
cidic residues did not bind heparan-BSA, thus demon-
trating the specificity of the interaction of gB-H-1 and
pK8.1A-H1 peptides with BSA-heparan (Fig. 9). The abil-
ty of gB-H1 peptide to bind heparan was more linear and
d
(
T
w
a
7
I
l tein ma
a iated H
243HHV-8 gB BINDS HEPARAN SULFATE-LIKE MOIETIESstronger than the gpK8.1A-H1, suggesting that gB-H1
peptide could represent a stronger HBD than the HBD of
gpK8.1A-H1 peptide. These results suggested the in-
volvement of HHV-8 gB amino acids 108–117 in the bind-
ing to HS-like moieties.
DISCUSSION
Glycoprotein B is one of the abundant herpesviral
glycoproteins crucial to the viral replication cycle (Spear,
1993). HHV-8 gB is expressed as an early late lytic gene
(Jenner et al., 2001). The following lines of evidence
presented in our study suggest that the interaction of
HHV-8 with cell-surface HS-like moieties (Akula et al.,
2001) could be in part mediated by the envelope-associ-
ated gB: (1) HHV-8 envelope-associated gB bound to
heparan-agarose beads, which was specifically eluted
by soluble heparan and not by chondroitin sulfate; (2) IVT
HHV-8 gB specifically bound to heparan-agarose, which
was blocked by HS and heparan, but not by other GAGs;
and (3) biotinylated gB peptide corresponding to the
putative HBD also bound heparan. Neutralization of
HHV-8 infectivity by rabbit anti-gB antibodies also show
that the viral envelope-associated gB plays a critical role
in the virus binding and entry process. Further work
using recombinant soluble gB without transmembrane
and carboxyl domains is in progress to examine the
FIG. 7. Displacement of HHV-8 envelope-associated gB from hepara
of 125I-labeled virion lysate with rabbit anti-gB IgG antibodies (lane 1) an
ith heparan-agarose beads. The unbound fraction was immunopre
ntibodies (lane 4). The heparan-agarose beads-bound fraction was inc
and 8) and further immunoprecipitated using rabbit anti-gB IgG (la
mmunoprecipitated samples were boiled in sample buffer with 2-ME,
eft indicate the molecular masses (in kilodaltons) of the standard pro
pproximate molecular mass (in kilodaltons) of major envelope-associnteractions of gB with cell-surface HS and other mole-
cules.
iWe demonstrated that gB was expressed throughout
the cytoplasm and on the surface membrane of the
HHV-8 infected cells. We also showed that gB is a virion
envelope-associated protein, consisting of 75 and 54
kDa polypeptides forming disulfide-linked heterodimers
and multimers. The 75 and 54 kDa polypeptides probably
derived from the cleavage of full-length gB precursor
molecule identified by Baghian et al. (2000). The differ-
ences in HHV-8 gB distribution detected in CHO-K1 cells
by Pertel et al. (1998) could be attributed to the differ-
ences in the cell type used and/or due to the possible
retention of HHV-8 gB-HA in the endoplasmic reticulum
by the HA tag. The expression of HHV-8 gB is similar to
gB of some members of the g2-herpesvirus subfamily,
such as equine herpesvirus-2 (EHV-2), EHV-5, and
BHV-4, but differ from gB of g1-EBV and g2-MHV-68.
Unlike anti-MHV-68 gB antisera which does not neutral-
ize MHV-68 infection (Stewart et al., 1994), rabbit anti-
HHV-8 gB antibodies were able to neutralize HHV-8 in-
fectivity, further demonstrating that gB is critical for virus
interaction with target cells. Our ongoing studies show
the inability of rabbit anti-gB antibodies even at a con-
centration of 1 mg/ml to inhibit the binding of [3H]thymi-
ine-labeled purified HHV-8 to a variety of cell lines
BJAB, BCBL, Raji, HFF, and 293 cells) (data not shown).
his suggests that anti-gB antibodies neutralize HHV-8
ose beads with soluble heparan. Lanes 1 and 2: immunoprecipitation
mune IgG antibodies (lane 2). The iodinated viral lysate was incubated
ed with rabbit anti-gB IgG antibodies (lane 3) and preimmune IgG
with 2 mg/ml of chondroitin sulfate C (lanes 5 and 6) or heparan (lanes
and 7) and preimmune IgG antibodies (lanes 6 and 8), respectively.
d by 7.5% SDS–PAGE gel, and autoradiographed. The numbers on the
rkers run in parallel lanes and the numbers on the right indicate the
HV-8 gB proteins.n-agar
d preim
cipitat
ubated
nes 5
analyzenfection at a postbinding step of infection.
Our studies have demonstrated the binding of biotin-
244 AKULA ET AL.
ae
b
f
o
d
s
a
p
245HHV-8 gB BINDS HEPARAN SULFATE-LIKE MOIETIESylated and 125I-labeled virion envelope-associated gB to
HS-like moieties. The IVT gB also bound specifically to
heparan and HS but not to other GAGs. Binding of un-
cleaved IVT products of gB and the synthetic peptides to
heparan suggests that cleavage of gB is not needed for
these interactions. The ability of nonglycosylated IVT gB
to bind heparan-agarose beads indicates that the glyco-
sylation modification of the protein is not essential for the
FIG. 8. (A) Binding of gB with heparan-agarose beads. The gB-pCDN
nd translated in the TNT system using rabbit reticulocyte lysates, [35S
and without 350 mg of various GAGs at 4°C for 1 h and then with hepara
luted by boiling in sample buffer, and resolved in a 7.5% SDS–PAGE. L
eads only. Lanes 3–9: IVT-gB pretreated with 350 mg of heparan (lane
chondroitin sulfate C (lane 7), N-acetyl heparan (lane 8), and de-N-su
numbers on the left indicate the approximate molecular mass (in kiloda
and glycosylated (G) forms of HHV-8 gB protein precipitated by hepara
IVT-gB to heparan-agarose beads in a dose-dependent manner. IV
membranes were incubated without (lane 1) or with 350, 175, 88, 44, 2
and then with heparan-agarose beads at 4°C for 2 h. These were was
7.5% SDS–PAGE, and autoradiographed. The numbers on the left indic
in parallel lanes. The IVT nonglycosylated (NG) and glycosylated (G) for
right. The percentage of heparan inhibition of gB binding to hepa
autoradiographic images with a transilluminator and by calculating w
heparan-agarose beads. IVT products from pCDNA3.1(1), gB-pCDNA3.1
were incubated with heparan-agarose beads at 4°C for 2 h, washed fi
SDS–PAGE, and autoradiographed. Lane 1: IVT products from pCDN
gL-pCDNA3.1(1) plasmid. Lane 3: IVT products from gL-pCDNA3.1
heparan-agarose beads. Lanes 5–7: IVT-gB products pretreated with 35
FIG. 9. Binding of biotinylated synthetic peptides corresponding to
the HBD of HHV-8 gB to heparan. Four peptides, gB-H-1 (HIFKVRRYRK,
108–117 aa), gB-H-2 (DAISVTECIN, 521–530 aa), gpK8.1A-H1
(TRGRDAHY, 182–189 aa), and gpK8.1A-H2 (SRTTRIRV, 150–157 aa)
were synthesized with biotin label at the N-terminus. 96-well plates
were coated with 1 mg/ml of BSA-heparan or BSA, incubated with
ifferent dilutions of biotinylated peptides, washed, reacted with the
ubstrate, and read in an ELISA reader at 450 nm. The values with BSA
lone were subtracted. Each reaction was done in triplicate and each
oint represents the average 6 SD of three experiments.or 1 h before incubating with heparan-agarose beads at 4°C for 2 h. The numb
f standard proteins run in parallel lanes. The IVT-nonglycosylated (NG) formprotein–heparan interaction. Neither N-acetyl heparan
nor de-N-sulfated heparan could competitively inhibit gB
binding to heparan-agarose beads, suggesting that
HHV-8 gB binding to heparan is dependent on N-sulfa-
tion of heparan and gB-heparan or gB-HS binding is a
charge-based interaction. Heparin and HS have a net
negative charge through N- and O-sulfation and bind
domains of protein with high positively charged regions
(Kjellen and Lindhl, 1991; Stringer and Gallagher, 1997).
Such charge-based interaction of HS with HHV-7 gp65
has been recently reported (Skrincosky et al., 2000).
The possible identity of the HBD within the extracel-
lular domain of gB was tested by using biotinylated
peptides. HHV-8 gB has a long extracellular domain
spanning from amino acid position 1 to 729, with basic
amino acid residues distributed throughout the se-
quence. Though we have identified a possible high-
affinity HBD within HHV-8 gB, we cannot rule out the
possibility of the presence of a set of multiple discrete
units of HBDs as proposed for pseudorabies virus gC
(Flynn and Ryan, 1996). It is also possible that several
other weak and/or high-affinity HBDs may appear within
HHV-8 gB in its native quaternary structure as the basic
amino acids separated may lie juxtaposed, forming a
typical HBD.
Our studies show that the putative HBD peptide of
HHV-8 envelope-associated gpK8.1A (Zhu et al., 1999a)
also binds to heparan. Further work is in progress to
characterize the gpK8.1A interaction with HS and hepa-
ran. Ongoing studies show that HHV-8 envelope-associ-
ated gpK8.1A also binds HS and that the 72-kDa protein
precipitated by heparan-agarose from the biotin-labeled
virus (Fig. 6, lane 2) represents HHV-8 gpK8.1A (manu-
script in preparation). The presence of two or more
plasmids and pCDNA3.1(1) control plasmids were in vitro transcribed
nine, and microsomal membranes. IVT products were incubated with
se beads at 4°C for 2 h. These were washed five times, bound material
IVT-gB with heparan-agarose beads only. Lane 2: IVT-gB with agarose
(lane 4), chondroitin sulfate A (lane 5), chondroitin sulfate B (lane 6),
heparan (lane 9) before the addition of heparan-agarose beads. The
f standard proteins run in parallel lanes. The IVT nonglycosylated (NG)
ose are indicated on the right. (B) Soluble heparan inhibits binding of
cts from gB-pCDNA3.1(1) plasmid in the presence of microsomal
11 mg/ml of soluble heparan (lanes 2, 3, 4, 5, 6, and 7) at 4°C for 1 h
times, bound material eluted by boiling in sample buffer, resolved by
approximate molecular mass (in kilodaltons) of standard proteins run
HV-8 gB protein precipitated by heparan-agarose are indicated on the
arose beads shown at the bottom was derived by capturing the
AlphaImager 2000 software program. (C) Nonglycosylated gB binds
d gL-pCDNA3.1(1) plasmids in the absence of microsomal membranes
s, bound material eluted by boiling in sample buffer, resolved by 7.5%
) plasmid with heparan-agarose beads. Lane 2: IVT products from
smid with heparan-agarose beads. Lane 4: IVT-gB products with
heparan (lane 5), HS (lane 6), and chondroitin sulfate C (lane 7) at 4°CA3.1(1)
]methio
n-agaro
ane 1:
3), HS
lfated
ltons) o
n-agar
T produ
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ran-ag
ith the
(1), an
ve time
A3.1(1
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0 mg ofers on the left indicate the approximate molecular mass (in kilodaltons)
of HHV-8 gB and gL proteins are indicated on the right.
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246 AKULA ET AL.heparan-binding glycoproteins within a single virus is
not unexpected, since all well-studied human a- and
b-herpesviruses contain at least two HS binding glyco-
proteins, e.g., gC and gB for HSV-1, HSV-2; gB and gCII
for HCMV; gB and gp65 for HHV-7 (Herold et al., 1994;
Navarro et al., 1993; Neyts et al., 1992; Secchiero et al.,
1997; Skrincosky et al., 2000; Spear, 1993). The presence
of two-HS binding proteins within the same virus indi-
cates the importance of cell-surface HS as receptors for
viral attachment. HSV-1 gC and gB exhibit differences in
their relative affinity for distinct cell-surface HS proteo-
glycans (Laquerre et al., 1998). Whether HHV-8 gB and
gpK8.1A also exhibit such differences needs to be stud-
ied.
MATERIALS AND METHODS
Cells
HFF, BCBL-1 cells (HHV-8 harboring human B cells)
(Renne et al., 1996), recombinant green fluorescence-
HHV-8 (GFP-HHV-8) harboring BCBL-1 cells (a gift from
Dr. Jeffrey Vieira, Fred Hutchinson Cancer Research
Center, Seattle) (Vieira et al., 2001), and BJAB cells
(HHV-8 negative human B cells) were used in this study.
HFF cell monolayers were grown in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco BRL, Grand Island, NY)
supplemented with 2 mM glutamine, 10% fetal bovine
serum (FBS), and antibiotics. BCBL-1 and BJAB suspen-
sion cells were grown in RPMI 1640 medium with glu-
taMAX I (Gibco BRL) supplemented with 10% FBS and
antibiotics. Spodoptera frugiperda ovarian cells (Sf9)
were grown in TNM-FH insect medium (PharMingen,
San Diego, CA).
Cloning of full-length gB gene
HHV-8 gB (ORF8) gene was amplified from the BCBL-1
cells by PCR using primers gB(F) 59-AGT GAG GAT CCA
CAA TGA CTC CCA GG-39 with a BamHI site and gB(R)
59-AGA ATG AAT TCT CAC TCC CCC GTT TCC G-39 with
an EcoRI site. The amplified fragment was cloned into
the BamHI/EcoRI sites of pCDNA3.1(1), an eukaryotic
expression vector (Invitrogen, Carlsbad, CA) containing
the HCMV immediate-early promoter to create the gB-
pCDNA3.1(1) clone. Clones were verified by sequencing.
Rabbit polyclonal antibodies
The full-length HHV-8 gB gene was subcloned into the
BamHI and EcoRI sites of the pAcGHLT-A baculovirus
vector (PharMingen) and cotransfected with Baculogold
DNA into Sf9 cells. The expression and purification of
GST-gB fusion protein were done using procedures de-
scribed previously (Zhu et al., 1999b). New Zealand white
male rabbits were immunized with the purified GST-gB
fusion protein. Rabbits were also immunized with bacu-
lovirus-expressed purified GST-HHV-8 latency-associ-ated ORF 73 protein and GST-HHV-8 envelope glycopro-
tein gL. Rabbit anti-IgG antibodies were purified from the
sera by affinity chromatography on a Protein A Sepha-
rose 4B column (Amersham Pharmacia Biotech AB, Upp-
sala, Sweden). To remove the nonspecific antibodies,
rabbit anti-gB IgG antibodies were passed repeatedly
over columns of Sepharose 4B coupled with the purified
GST protein and BJAB cell lysate proteins.
In vitro transcription and translation
One microgram gB-pCDNA3.1(1) DNA was used in the
IVT experiments using [35S]methionine and TNT-coupled
abbit reticulocyte lysate system (Promega, Madison, WI)
ith and without canine pancreatic microsomal mem-
ranes according to the manufacturer’s recommenda-
ions. IVT products were boiled in sample buffer with
-mercaptoethanol (2-ME), and equal trichloroacetic acid
TCA) precipitable counts were analyzed by 10% SDS–
AGE. The gels were stained with Coomassie blue,
estained, treated with the intensify solutions (NEN Life
cience Products, Inc, Boston, MA), dried onto a filter
aper, and exposed to a Kodak (X-OMAT, AR) film at
70°C.
mmunofluorescence assay (IFA)
12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma,
t.Louis, MO)-induced BCBL-1 and BJAB cells were col-
ected after 4 days postinduction, washed, fixed with
cetone, and used in IFA as per the method described
reviously (Chandran et al., 1998, Zhu et al., 1999a).
urface immunofluorescence assay (SIFA)
TPA-induced BCBL-1 and BJAB cells (4 days postin-
uction) fixed with 0.1% paraformaldehyde was used to
xamine the cell-surface expression of gB as per the
ethod described previously (Zhu et al., 1999a).
mmune electron microscopy
Immune electron microscopy (IEM) was done as per
he method described previously (Zhu et al., 1999a).
riefly, BCBL-1 cells stimulated with TPA for 24 or 92 h
ere fixed with 0.1% paraformaldehyde, washed, and
ncubated with anti-gB antibodies at 37°C for 30 min.
ells were washed and incubated with anti-rabbit anti-
odies conjugated with 15-nm gold particles at 37°C for
0 min. These cells were fixed with glutaraldehyde and
mbedded in resins, and thin sections were made and
bserved under an electron microscope.
125I-labeling of HHV-8
HHV-8 from the culture supernatant of TPA-induced
BCBL-1 cells (6 days postinduction) was concentrated
and purified as per the method described previously
(Akula et al., 2001). Purified virus was repelleted at
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247HHV-8 gB BINDS HEPARAN SULFATE-LIKE MOIETIES100,000 g at 4°C for 1 h. The pellet was suspended in a
small volume of PBS and labeled at room temperature for
15 min with 1.0 mCi of 125I (Amersham Pharmacia Biotech,
iscataway, NJ) and iodo-beads (Pierce, Rockford, IL).
he iodinated virus was pelleted at 100,000 g at 4°C for
90 min and the pellet was resuspended in RIPA lysis
buffer [0.05 M Tris–HCl pH 7.5, 0.15 M NaCl, 1% sodium
deoxycholate, 1% Triton X-100, 100 U/ml Aprotinin, 0.1
mM phenylmethylsulfonyl fluoride] (Chandran et al.,
1998). The iodinated viral lysate was sonicated on ice for
1 min and centrifuged again at 100,000 g at 4°C for 90
min. The resulting supernatant containing the soluble
labeled proteins was stored at 280°C.
Radioimmunoprecipitation
Radioimmunoprecipitation (RIP) was performed as per
the method described previously (Shaw et al., 2000).
Equal TCA precipitable counts of [35S]methionine-labeled
VT products or 125I-labeled virion lysate were mixed with
antibodies and Protein A–Sepharose 4B beads. The pre-
cipitates were washed five times with RIPA buffer. Immu-
noprecipitated samples were boiled in sample buffer
with (reduced condition) or without (nonreduced condi-
tion) 2-ME. Samples containing equal radioactive counts
were resolved by 7.5 or 10% SDS–PAGE and examined by
autoradiography.
Neutralization of HHV-8
To monitor the HHV-8 binding and entry process,
BCBL-1 cells carrying GFP-HHV-8 was established
(Vieira et al., 2001). Expression of GFP was under the
control of the promiscuous elongation factor-1-a pro-
oter. Stable GFP-BCBL-1 cells were easily monitored
y fluorescence microscopy (Vieira et al., 2001). GFP-
HV-8 in the supernatant of TPA-induced GFP-BCBL-1
ells was concentrated as previously described (Akula et
l., 2001; Vieira et al., 2001) and used as the inoculum for
nfection. GFP-HHV-8 titer was estimated using HFF and
93 cell monolayers (Vieira et al., 2001). Three days
ostinfection, GFP-expressing cells in eight-well cham-
er slides (Nagle Nunc International, Naperville, IL) were
bserved by fluorescence microscopy and enumerated.
o determine the effect of anti-gB IgG antibodies on
FP-HHV-8 infectivity, 100 ml of GFP-HHV-8 was incu-
bated at 37°C for 1 h with DMEM alone or with DMEM
containing different concentrations of IgG antibodies (0,
7.5, 15, 30, and 60 mg/ml). This mixture was added to HFF
ell monolayers in eight-well chamber slides, incubated
t 37°C for 2 h, washed twice, and incubated with growth
edium. After 3 days, slides were examined by a Nikon
clipse TE300 inverted fluorescent microscope. Green
luorescent cells indicative of GFP-HHV-8 entry and in-
ection were counted using Nikon Magna Firewire digital
maging system. Each reaction was done in triplicate and
epeated three times.estern blot assays
Samples were boiled in sample buffer with 2-ME, run
n SDS–PAGE, and electrophoretically transferred onto
itrocellulose membranes. Standard prestained molecu-
ar weight markers (Gibco BRL) were included in parallel
anes. The membranes were soaked in blocking solution
10 mM Tris–HCl, pH 7.2, 150 mM NaCl, 5% skim milk or
% BSA, 0.02% Na N3) at 4°C overnight and then reacted
with antibodies for 3 h at room temperature. The mem-
branes were washed five times with washing buffer (10
mM Tris–HCl pH 7.2, 150 mM NaCl, 0.3% Tween 20) and
incubated for 1 h with alkaline phosphatase (AP)-conju-
gated secondary antibodies (KPL, Gaithersburg, MD).
Bound enzyme-labeled antibodies were detected by
color reaction of AP with nitroblue tetrazolium and 5-bro-
mo-4-chloro-3-indolyphosphate substrates (Sigma). The
reactions were stopped by washing the membranes in
distilled water.
Virion envelope-associated gB binding with heparan-
agarose
Purified HHV-8 (Akula et al., 2001; Zhu et al., 1999a)
as labeled with biotin as per the manufacturer’s rec-
mmendations (Gibco BRL). The free biotin was removed
y extensive dialysis first against 0.5 M sodium carbon-
te buffer (pH 9.0) and then against PBS (pH 7.4). Cell
inding activity of biotinylated virus was tested by SIFA
sing BJAB cells as per the method described above and
ound virus was detected by FITC-conjugated streptavi-
in. To test the binding activity with heparan-agarose, the
iotinylated virus preparation was lysed with RIPA buffer,
onicated, and centrifuged at 100,000 g at 4°C for 1 h.
The resulting supernatant containing the soluble biotin-
ylated envelope proteins was mixed with 100 ml of a 50%
lurry of heparan-agarose or agarose beads in RIPA
uffer at 4°C for 2 h. The beads were washed five times
n RIPA buffer, boiled in sample buffer with 2-ME, re-
olved by 10% SDS–PAGE, Western blotted, and analyzed
ith AP-conjugated streptavidin (DAKO, Carpinteria, CA)
nd substrate or with rabbit IgG antibodies followed by
P-labeled secondary antibodies and substrate.
ffinity chromatography of virion envelope-associated
B binding with heparan-agarose
The experiment was performed as per the method
escribed by Vanderplasschen et al. (1993) with minor
odifications. 125I-labeled HHV-8 lysates (0.4 ml, 8 3 106
cpm) were incubated by constant mixing with 100 ml of
50% heparan agarose beads at 4°C for 1 h. The samples
were centrifuged at 13,000 g (IEC, Micromax, Needham
Heights, MA) at 4°C for 30 s. The supernatants repre-
senting the unbound fractions were collected. The beads
were washed four times with RIPA buffer and the bound
fractions eluted by incubating the heparan-agarose
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248 AKULA ET AL.beads at room temperature for 10 min with chondroitin
sulfate or heparan (1 mg in 0.5 ml of RIPA buffer). The
beads were centrifuged again at 13,000 g 4°C for 30 s,
and the supernatants representing the bound fraction
collected. The heparan-agarose unbound and bound
fractions were immunoprecipitated with rabbit anti-gB
and preimmune IgG antibodies. Immunoprecipitated
samples were boiled in sample buffer with 2-ME, re-
solved by 7.5% SDS–PAGE, and examined by autoradiog-
raphy.
Analysis of HHV-8 gB binding to heparan–agarose
The [35S]methionine-labeled IVT products from the gB-
pCDNA3.1(1) plasmid in the presence or absence of the
microsomal membranes were untreated or treated with
350 mg of various GAGs, such as heparan, HS, chon-
roitin sulfate A, chondroitin sulfate B, chondroitin sulfate
, N-acetyl heparan, and de-N-sulfated heparan (Sigma).
fter mixing at 4°C for 1 h, 100 ml of a 50% slurry of
eparan-agarose beads (Sigma) equilibrated in RIPA
uffer was added and further mixed at 4°C for 2 h. The
eparan-agarose beads were washed five times in RIPA
uffer. The bound material was eluted by boiling the
eads in sample buffer, resolved by 7.5% SDS–PAGE, and
xamined by autoradiography. Inhibition of gB binding to
eparan-agarose beads was assessed by preincubating
he IVT products from the gB-pCDNA3.1(1) plasmid with
50, 175, 88, 44, 22, 11 mg/ml of soluble heparan. The
utoradiographic images were captured by a Transillu-
inator TM-20 (Alpha Innotech Corp., San Leandro, CA)
nd the percentage inhibition of gB binding to heparan-
garose beads was measured using the AlphaImager
000 software program.
mino acid analysis and motif comparisons
Amino acid analysis and motif comparisons were per-
ormed using the software and database from the Protein
nformation Resource (Barker et al., 2000).
valuation of heparan-binding properties of synthetic
eptides
The gB-H1 (HIFKVRRYRK, 108–117 aa), gB-H2 (DAIS-
TECIN, 521–530 aa), gpK8.1A-H1 (TRGRDAHY, 182–189
a), and gpK8.1A-H2 (SRTTRIRV, 150–157 aa) were syn-
hesized with biotin labeled at the N-termini (Syn Pep
orp., Dublin, CA). To assess the heparan-binding prop-
rty of these biotinylated peptides, 96-well MAXISORP
lates (Nunclon, Rochester, NY) were coated with 50 ml
f 1 mg/ml BSA-heparan (Sigma) or BSA (Sigma) at 4°C
vernight. After washing and blocking the wells with 5%
onfat dry milk, 50 ml of different concentrations of bio-
inylated peptides was added to the wells and incubated
or 1 h at room temperature. The wells were rinsed withash buffer and treated with the ABC reagent and
,39,5,59-tetramethyl benzidine (TMB substrate) solutions per the manufacturer’s recommendations (Pierce).
he plates were read in an ELISA reader at 450 nm. Each
eaction was done in triplicate and the values with BSA
lone were subtracted.
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